vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Qfin Holdings, Inc. (QFIN). Click either name above to swap in a different company.
Qfin Holdings, Inc. is the larger business by last-quarter revenue ($731.2M vs $406.6M, roughly 1.8× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 27.5%, a 33.0% gap on every dollar of revenue. Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 16.4%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Qfin Holdings Inc. is a leading China-based fintech enterprise that mainly provides intelligent credit solutions, risk management technology support, and digital financial service tools. It collaborates with licensed financial institutions to serve individual consumers and micro, small and medium-sized enterprises across China, using big data and artificial intelligence to boost financial inclusion and operational efficiency.
BCRX vs QFIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $406.6M | $731.2M |
| Net Profit | $245.8M | $201.2M |
| Gross Margin | 97.7% | — |
| Operating Margin | 64.0% | 32.7% |
| Net Margin | 60.5% | 27.5% |
| Revenue YoY | 209.1% | — |
| Net Profit YoY | 1017.5% | — |
| EPS (diluted) | $1.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $406.6M | — | ||
| Q3 25 | $159.4M | $731.2M | ||
| Q2 25 | $163.4M | $728.1M | ||
| Q1 25 | $145.5M | $646.4M | ||
| Q4 24 | $131.5M | — | ||
| Q3 24 | $117.1M | $622.7M | ||
| Q2 24 | $109.3M | $572.4M | ||
| Q1 24 | $92.8M | $575.2M |
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | $201.2M | ||
| Q2 25 | $5.1M | $241.6M | ||
| Q1 25 | $32.0K | $247.6M | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | $256.3M | ||
| Q2 24 | $-12.7M | $189.4M | ||
| Q1 24 | $-35.4M | $160.7M |
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 98.6% | — |
| Q4 25 | 64.0% | — | ||
| Q3 25 | 18.6% | 32.7% | ||
| Q2 25 | 18.2% | 41.0% | ||
| Q1 25 | 14.6% | 42.1% | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | 6.6% | 52.4% | ||
| Q2 24 | 8.0% | 47.7% | ||
| Q1 24 | -15.6% | 32.8% |
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | 27.5% | ||
| Q2 25 | 3.1% | 33.2% | ||
| Q1 25 | 0.0% | 38.3% | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | 41.2% | ||
| Q2 24 | -11.6% | 33.1% | ||
| Q1 24 | -38.1% | 27.9% |
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.06 | — | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.7M | $6.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-119.2M | $24.3B |
| Total Assets | $514.2M | $61.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $274.7M | — | ||
| Q3 25 | $212.9M | $6.5B | ||
| Q2 25 | $260.0M | $5.3B | ||
| Q1 25 | $295.1M | $8.6B | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | $4.3B | ||
| Q2 24 | $78.4M | $6.3B | ||
| Q1 24 | $84.3M | $5.3B |
| Q4 25 | $-119.2M | — | ||
| Q3 25 | $-387.9M | $24.3B | ||
| Q2 25 | $-421.6M | $24.1B | ||
| Q1 25 | $-451.9M | $23.1B | ||
| Q4 24 | $-475.9M | — | ||
| Q3 24 | $-468.6M | $22.9B | ||
| Q2 24 | $-475.6M | $22.6B | ||
| Q1 24 | $-476.2M | $22.1B |
| Q4 25 | $514.2M | — | ||
| Q3 25 | $446.4M | $61.4B | ||
| Q2 25 | $457.2M | $59.8B | ||
| Q1 25 | $480.0M | $55.6B | ||
| Q4 24 | $490.4M | — | ||
| Q3 24 | $491.3M | $47.0B | ||
| Q2 24 | $472.4M | $47.0B | ||
| Q1 24 | $467.9M | $47.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $292.0M | $351.4M |
| Free Cash FlowOCF − Capex | $291.2M | — |
| FCF MarginFCF / Revenue | 71.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.19× | 1.75× |
| TTM Free Cash FlowTrailing 4 quarters | $344.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $292.0M | — | ||
| Q3 25 | $41.6M | $351.4M | ||
| Q2 25 | $41.3M | $366.0M | ||
| Q1 25 | $-27.5M | $386.6M | ||
| Q4 24 | $-5.2M | — | ||
| Q3 24 | $8.2M | $338.0M | ||
| Q2 24 | $-1.4M | $269.9M | ||
| Q1 24 | $-53.7M | $271.2M |
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-53.9M | — |
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | -58.1% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | 1.75× | ||
| Q2 25 | 8.12× | 1.52× | ||
| Q1 25 | -859.91× | 1.56× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.43× | ||
| Q1 24 | — | 1.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
